Catalysts from several late-stage projects including those from Astrazeneca, Sanofi, Allakos and Celldex aim to shake up the market.
The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
The anti-Ox40 ligand antibody amlitelimab could have its work cut out to best the company’s own Dupixent.
Strong mid-stage data seem to show sonelokimab, a Merck KGaA cast-off, beating bigger rivals.
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.